Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR30303 in Advanced Solid Tumors
NCT05639153Phase 1Terminated
- Sponsor
- Doer Bio
- Start
- May 2022
- Primary completion
- Dec 2025
- Modality
- Antibody-Drug Conjugates (ADCs), Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DR30303 in solid tumor, gastric cancer (GC), gastroesophageal junction cancer and 1 more, sponsored by Doer Bio. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events at 28 days and 2 more. Started May 2022; status: terminated.
02
Drugs
DR30303
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05639153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639153.